Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation.

Although the overall prevalence of patients with increased leaflet 18 F-NaF uptake appeared to be nearly double in patients with SAVR (29% versus 15% in those with TAVI), this did not reach statistical significance ( P =0.09), and, in those studied at 5 years, there was no difference in the proportion of patients demonstrating bioprosthetic uptake (40% patients with SAVR versus 44% patients with TAVI; P =0.79).

also in 111,027 other papers